Predictive Therapeutics Press Release Archive

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES INITIAL MEMBERS OF FINANCIAL ADVISORY BOARD

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES INITIAL MEMBERS OF FINANCIAL ADVISORY BOARD

Salt Lake City, UT- Predictive Technology Group, Inc. (PRED.OTC), a life sciences technology holding Company, announces initial members of its “Financial Advisory Board.”

In conjunction with closing LifeCode Genetics, Inc. acquisition, Predictive Technology Group, Inc. has formed a “Financial Advisory Board.” These initial board members were the early investors/shareholders of LifeCode Genetics, Inc., who now own PRED shares post acquisition.

The three initial Financial Advisory Board members are as follows:

Dr. Gregory A. Prince – Pioneered the prevention of respiratory syncytial virus (RSV) disease in high-risk infants through the use of monoclonal antibody (SynagisÒ is currently marketed through a partnership between MedImmune and Abbvie); DDS and PhD (pathology) at UCLA; post-doctoral fellowship at the National Institutes of Health; CEO Virion Systems; National Advisory Councils, Johns Hopkins University School of Education, Utah Valley University, Dixie State University (chair); author of over 150 scientific publications in the field of infectious diseases.

Ronald Barhorst – Retired President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies.  Mr. Barhorst currently serves as Chairman on the California State University Foundation Board of Governors.

Jonas Cedergren – Managing Director, JC Capital.  He was previously Managing Director, Head of European Equity Derivatives, and Head of Northern Europe, Barclays Capital, London, Managing Director and Head of Nordics, Credit Suisse, London and Vice President, Bankers Trust. Previous Board Member of Enter Card Europe.

Bradley Robinson, President, Predictive Technology Group, Inc., states, “The commitment and wealth of experience of the members of the ‘Financial Advisory Board’ will bring valued governance and guidance. As PRED moves forward with commercialization of its diagnostics and therapeutics, in its mission of revolutionizing patient care through novel gene-base companion diagnostics and therapeutics, these ‘Financial Advisory Board’ members will provide support and advice in PRED’s current and future business direction.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions.  PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements 
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES ACQUISITION OF LIFECODE GENETICS, INC.

Virginia Beach, VA- Predictive Technology Group, Inc. (PRED.OTC), a life sciences technology holding Company, announces that it acquired LifeCode Genetics, Inc. (“LifeCode”).  LifeCode, a Nevada corporation established in 2011, develops and commercializes gene-based diagnostics.

LifeCode holds strategic gene-based diagnostic assets, which can assist mothers in having healthier pregnancies and, ultimately, healthier babies.

Bradley Robinson, President, Predictive Technology Group, Inc., states, “This acquisition complements the business strategy at PRED.  We look for novel assets which can improve quality of human life.”

Through an equity transaction, LifeCode is now a fully owned subsidiary of Predictive Technology Group, Inc.

PRED’s mission of revolutionizing patient care through novel gene-based companion diagnostics and therapeutics, continues forward with the acquisition of LifeCode Genetics, Inc.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions.  PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements 
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc. (PRED) Announces Issuance of US Patent for Endometriosis Treatment

Virginia Beach,  VA – November 17, 2015- Predictive Technology Group, Inc. (OTCPINKS: PRED), a biotechnology company focused on personalized patient care through novel gene-based companion diagnostics and therapeutics, announces that the United States Patent and Trademark Office has issued US Patent 9,149,499 covering Progesterone/Progestin/Cannabis Therapeutic and Method of Use for the treatment of endometriosis.  Predictive Therapeutics, LLC, a subsidiary of PRED, has exclusive rights to the patent.

About Endometriosis

According to the “The World Endometriosis Research Foundation,” endometriosis affects an estimated 1 in 10 women during their reproductive years (i.e., usually between the ages of 15 to 49).    Endometriosis is a condition where tissue, called endometrium, which lines the uterus is found outside the uterus inducing a chronic inflammatory reaction that may result in scar tissue. Endometriosis affects an estimated 176 million women worldwide regardless of their ethnic and social background. Many remain undiagnosed and are therefore not treated (http://endometriosisfoundation.org/Facts-about-endometriosis.pdf).
About Predictive Therapeutics

Predictive Technology Group, Inc. (“PRED”) is a life sciences holding company.  Predictive Therapeutics, LLC (“PRx”), a subsidiary of PRED, is focused on novel therapeutics leveraged by proprietary gene-based companion diagnostics that provide for the delivery of the most appropriate personalized patient care for the treatment of serious, chronic and debilitating diseases, www.predrx.com and www.predictivetechnologygroup.com.

For further information contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.